DrAnneliese Ashhurst

There is no cure for inflammatory skin diseases which are costly and debilitating. Immune suppression is the only treatment option, but current therapies are expensive, can cause serious side-effects and are not always efficacious. Dr Ashhurst's research aims to develop next generation therapeutics that are safer, readily accessible and preferentially suppress local inflammation. She is committed to interdisciplinary research to achieve translational outcomes that could not be realised within a single discipline, pursuing innovative projects in collaboration with specialists in pharmaceutical science and chemistry.

Dr Ashhurst also has expertise in inflammatory responses at the pulmonary mucosa (lungs), particularly in response to infectious diseases such as tuberculosis, which remains the world's leading infectious disease killer, and other common respiratory viral pathogens such as SARS-CoV-2, influenza and RSV. She has an interest in developing vaccines and drugs designed for inhalation.